In addition, the current screening approach was also able to identify other cardiac GPCRs that have already been investigated in the context of HF, and that antagonists of Cysltr1, i.e., montelukast or zafirlukast could be potential candidates of drug repurposing for a novel indication in HF, which deserves further investigation. Here, CYSLTR1 is linked to hydrops fetalis.